Abstract
Since telomere integrity is required to guarantee the unlimited replicative potential of cancer cells, telomerase, the enzyme responsible for telomere length maintenance in most human tumors, and lately also telomeres themselves have become extremely attractive targets for new anticancer interventions. At the current status of knowledge, it is still not possible to define the best therapeutic target between telomerase and telomeres. It is noteworthy that interfering with telomeres, through direct targeting of telomeric DNA or proteins involved in the telosome complex, could negatively affect the proliferative potential not only of tumors expressing telomerase activity but also of those that maintain their telomeres through alternative lengthening or still unknown mechanisms. This review presents the different therapeutic approaches proposed thus far and developed in preclinical tumor models and discusses the perspectives for their use in the clinical setting.
| Original language | English |
|---|---|
| Pages (from-to) | 309-316 |
| Number of pages | 8 |
| Journal | Biochimica et Biophysica Acta - Molecular Basis of Disease |
| Volume | 1792 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2009 |
Fingerprint
Keywords
- Cancer
- G-quadruplex
- Telomerase
- Telomere
- Telosome
ASJC Scopus subject areas
- Molecular Biology
- Molecular Medicine
Cite this
Targeting the telosome : Therapeutic implications. / Folini, Marco; Gandellini, Paolo; Zaffaroni, Nadia.
In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1792, No. 4, 04.2009, p. 309-316.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Targeting the telosome
T2 - Therapeutic implications
AU - Folini, Marco
AU - Gandellini, Paolo
AU - Zaffaroni, Nadia
PY - 2009/4
Y1 - 2009/4
N2 - Since telomere integrity is required to guarantee the unlimited replicative potential of cancer cells, telomerase, the enzyme responsible for telomere length maintenance in most human tumors, and lately also telomeres themselves have become extremely attractive targets for new anticancer interventions. At the current status of knowledge, it is still not possible to define the best therapeutic target between telomerase and telomeres. It is noteworthy that interfering with telomeres, through direct targeting of telomeric DNA or proteins involved in the telosome complex, could negatively affect the proliferative potential not only of tumors expressing telomerase activity but also of those that maintain their telomeres through alternative lengthening or still unknown mechanisms. This review presents the different therapeutic approaches proposed thus far and developed in preclinical tumor models and discusses the perspectives for their use in the clinical setting.
AB - Since telomere integrity is required to guarantee the unlimited replicative potential of cancer cells, telomerase, the enzyme responsible for telomere length maintenance in most human tumors, and lately also telomeres themselves have become extremely attractive targets for new anticancer interventions. At the current status of knowledge, it is still not possible to define the best therapeutic target between telomerase and telomeres. It is noteworthy that interfering with telomeres, through direct targeting of telomeric DNA or proteins involved in the telosome complex, could negatively affect the proliferative potential not only of tumors expressing telomerase activity but also of those that maintain their telomeres through alternative lengthening or still unknown mechanisms. This review presents the different therapeutic approaches proposed thus far and developed in preclinical tumor models and discusses the perspectives for their use in the clinical setting.
KW - Cancer
KW - G-quadruplex
KW - Telomerase
KW - Telomere
KW - Telosome
UR - http://www.scopus.com/inward/record.url?scp=64249083673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=64249083673&partnerID=8YFLogxK
U2 - 10.1016/j.bbadis.2009.01.014
DO - 10.1016/j.bbadis.2009.01.014
M3 - Article
C2 - 19419699
AN - SCOPUS:64249083673
VL - 1792
SP - 309
EP - 316
JO - Biochimica et Biophysica Acta - Molecular Basis of Disease
JF - Biochimica et Biophysica Acta - Molecular Basis of Disease
SN - 0925-4439
IS - 4
ER -